Autoimmune liver diseases

Minerva Pediatrica

Volumn 64, Issue 6, 2012, Pages 595-606

  Della Corte, C ^a   Sartorelli, M R ^a   Comparcola, D ^a   Alterio, A ^a   Giorgio, V ^a   Papadatou, B ^a   Nobili, V ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Child; Immunosuppression; Liver diseases

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN G; MICROSOME ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ACNE; ACUTE HEPATITIS; ACUTE LIVER FAILURE; ACUTE PANCREATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; BODY WEIGHT; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN DISEASE; CATARACT; CHILD; CHRONIC DRUG ADMINISTRATION; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA DISEASE; GUM HYPERTROPHY; HAIR LOSS; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; JAUNDICE; KIDNEY FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MUSCLE ATROPHY; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PORTAL HYPERTENSION; PSYCHOSIS; RASH; REVIEW; SCLEROSING CHOLANGITIS; SEIZURE; SIDE EFFECT; SPLENOMEGALY; STEROID THERAPY; TREATMENT WITHDRAWAL; VOMITING; WEIGHT REDUCTION;

ALGORITHMS; AUTOIMMUNE DISEASES; CHILD; HEPATITIS; HUMANS; LIVER DISEASES;

EID: 84873492530     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
2. Waldenström JL. Blutproteine und Nahrungseiweiss. Dtsch Z Verdau Staffwechselkr 1950;15:113-9.
3. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? Semin Liver Dis 2009;29:297-306.
4. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011;55:171-82.
5. Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011;8:320-9.
6. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040-8.
7. Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol 2009;43:787-90.
8. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010;44:e20-2.
9. Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report. J Crohns Colitis 2011;5:253-5.
10. Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997;92:703-4. (Pubitemid 27184395)
11. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004;53:599-608. (Pubitemid 38372988)
12. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22:353-64.
13. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002;6:727-37.
14. Vorechovsky I, Webster AD, Plebani A, Hammarstrom L. Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am J Hum Genet 1999;64:1096-109. (Pubitemid 30463041)
15. Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25:653-64.
16. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory Tcells in autoimmune liver disease. J Hepatol 2004;41:31-7. (Pubitemid 39005149)
17. Krawitt EL. Discrimination of autoimmune hepatitis: autoantibody typing and beyond. J Gastroenterol 2011;46(Suppl 1):39-41.
18. Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009;29:241-53.
19. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7. (Pubitemid 27106430)
20. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64. (Pubitemid 34183971)
21. Vergani, D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677-83. (Pubitemid 39297806)
22. Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009;49:158-64.
23. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:329-38.
24. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76. (Pubitemid 351975541)
25. Hiejima E, Komatsu H, Sogo T, Inui A, Fujisawa T. Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children. J Pediatr Gastroenterol Nutr 2011;52:470-3.
26. Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children - What is different from adulthood? Best Pract Res Clin Gastroenterol 2011;25:783-95.
27. Gassert DJ, Tanaka HGK, Reinus JF. Corticosteroid-Responsive Cryptogenic Chronic Hepatitis: Evidence for Seronegative Autoimmune Hepatitis. Dig Dis Sci 2007;52:2433-7. (Pubitemid 47246512)
28. Radhakrishnan KR, Alkhouri N, Worley S, Arrigain S, Hupertz V, Kay M et al. Autoimmune hepatitis in children-impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis 2010;42:724-8.
29. Alvarez F. Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis 2006;10:89-107. (Pubitemid 41821379)
30. Ferreira AR, Roquete ML, Toppa NH, de Castro LP, Fagundes ED, Penna FJ. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2008;46:65-70.
31. Kerkar N, Annunziato RA, Foley L, Schmeidler J, Rumbo C, Emre S et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006;43:629-34. (Pubitemid 44863690)
32. Samaroo B, Samyn M, Buchanan C. Long-term daily oral treatment with prednisolone in children with autoimmune liver disease does not affect final adult height. Hepatology 2006;44:438A.
33. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54-66. (Pubitemid 43048951)
34. Vergani D, Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2011;12:607-13.
35. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J. Hepatol 2004;40:646-52. (Pubitemid 38367787)
36. Bluth MH, Kohlhoff S, Norowitz KB, Silverberg JI, Chice S, Nowakowski M et al. Immune responses in autoimmune hepatitis: effect of prednisone and azathioprine treatment: case report. Int J Med Sci 2009;6:177-83.
37. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009;68:1833-8.
38. Vergani D, Longi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009;31:421-35.
39. Kanzler S, Gerken G, Löhr H, Galle PR, Mayer zum Büschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis (AIH). J Hepatol 2001;34:354-5.
40. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011;55:636-46.
41. Baven-Pronk AMC, Coenraad MJ, van Buuren HR, de Man RA, van Erpecum KJ, Lamers MMH et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011;34:335-43.
42. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-years follow up. J Hepatol 2009;51:156-60.
43. Schramm C, Lohse AW. Role of mycophenolate mofetil in the treatment of autoimmune hepatitis. J Hepatol 2011;55:510-1.
44. Tannous MM, Cheng J, Muniyappa K, Farooq I, Bharara A, Kappus M et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011;34:405-7.
45. Damoiseaux JC, van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol 1998;44:1-9.
46. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40:3-7. (Pubitemid 38064706)
47. Alvarez F, Ciocca M, Cañero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7. (Pubitemid 29071183)
48. Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, González T, López S et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43:635-9. (Pubitemid 44863691)
49. Sciveres M, Caprai S, Palla G, Ughi C, Maggiore G. Effectiveness and safety of cyclosporine therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004;19:209-17. (Pubitemid 38174890)
50. Debray D, Maggiore G, Giradet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatits. J Pediatr 1999;135:111-4. (Pubitemid 30180574)
51. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13. (Pubitemid 34032538)
52. Manns MP, Woynarowski M, Kreisler W, Lurie Y, Rust C, Zuckerman E et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
53. Martin SR, Alvarez F, Anand R, Song C, Yin W; SPLIT Research Group. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl 2011;17:393-401.
54. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32. (Pubitemid 29300604)
55. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53. (Pubitemid 32185215)
56. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-7. (Pubitemid 36775813)
57. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990;12:486-91. (Pubitemid 20382016)
58. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep 2002;4:37-44.
59. Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2011;24:573-89.
60. Ibrahim SH, Lindor KD. Current management of primary sclerosing cholangitis in pediatric patients. Pediatr Drugs 2011;13:87-95.
61. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of highdose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7. (Pubitemid 32959399)
62. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.
63. Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011;34:1185-92.
64. Shneider BL. Diagnostic and therapeutic challenges in pediatric primary sclerosing cholangitis. Liver Transpl 2012;18:277-81.
65. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35:515-9. (Pubitemid 36321892)
66. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13. (Pubitemid 28064165)
67. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40:3-7. (Pubitemid 38064706)
68. Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr Pharm Des 2011;17:3120-40.
69. Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011;53:536-47.